Literature DB >> 19180130

An outbreak of diarrhea-associated childhood hemolytic uremic syndrome: the Walkerton epidemic.

Douglas G Matsell1, Colin T White.   

Abstract

In Canada, the majority of cases of childhood hemolytic uremic syndrome (HUS) are associated with a diarrheal illness (D+) due to verotoxin-producing Escherichia coli (VTEC). Although the ingestion of undercooked beef is an important cause, we report on the largest outbreak of E. coli illness due to a contaminated supply of municipal water. We describe the clinical features and short-term outcomes of 22 children who simultaneously developed D+HUS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19180130     DOI: 10.1038/ki.2008.628

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  4 in total

1.  Evaluation of enzyme immunoassays and real-time PCR for detecting Shiga toxin-producing Escherichia coli in Southern Alberta, Canada.

Authors:  Linda Chui; Laura Patterson-Fortin; Julie Kuo; Vincent Li; Valerie Boras
Journal:  J Clin Microbiol       Date:  2015-01-14       Impact factor: 5.948

2.  Molecular profiling of Escherichia coli O157:H7 and non-O157 strains isolated from humans and cattle in Alberta, Canada.

Authors:  Linda Chui; Vincent Li; Patrick Fach; Sabine Delannoy; Katarzyna Malejczyk; Laura Patterson-Fortin; Alan Poon; Robin King; Kimberley Simmonds; Allison N Scott; Mao-Cheng Lee
Journal:  J Clin Microbiol       Date:  2014-12-24       Impact factor: 5.948

3.  Impact of platelet transfusions in children with post-diarrheal hemolytic uremic syndrome.

Authors:  Alejandro Balestracci; Sandra Mariel Martin; Ismael Toledo; Caupolican Alvarado; Raquel Eva Wainsztein
Journal:  Pediatr Nephrol       Date:  2013-02-06       Impact factor: 3.714

Review 4.  Outbreaks of virulent diarrheagenic Escherichia coli--are we in control?

Authors:  Dirk Werber; Gérard Krause; Christina Frank; Angelika Fruth; Antje Flieger; Martin Mielke; Lars Schaade; Klaus Stark
Journal:  BMC Med       Date:  2012-02-02       Impact factor: 8.775

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.